New Study: Elevated CRP Linked to Developing Chronic Pain in Older Adults

Chronic pain is one of the most common and costly health challenges in older adults, affecting quality of life, sleep, mobility, and mental health all at once. For decades, researchers have suspected that inflammation plays a role in how pain becomes persistent, based partly on the observation that anti-inflammatory drugs provide at least some relief across many pain conditions. But pinning down exactly how much of the risk in real people is attributable to measurable inflammation markers has proven difficult. A new study published in October 2026 takes a carefully designed longitudinal look at that question, following older adults over several years to see whether CRP levels could predict who would develop chronic pain, and the results are informative even where they disappoint.

What the New Study Found

The research team used data from the Health and Retirement Study, a nationally representative panel survey of Americans over 50 that collects health, biomarker, and quality-of-life data every two years. From this dataset, the authors identified 1,850 adults who reported no chronic pain and had not been diagnosed with arthritis at the start of the observation period, then followed them from 2016 through 2022 to see who developed chronic pain. At baseline, CRP had been measured as part of the study's biomarker protocol, giving the researchers a clean prospective design: they knew who was pain-free, what their inflammation levels looked like, and could track what happened afterward.

After adjusting for major confounders including age, sex, body mass index, depression, and other health conditions, CRP remained a statistically significant predictor of incident chronic pain. The incidence rate ratio was 1.10 (95% confidence interval: 1.01 to 1.20), meaning that for each unit increase in CRP, the rate of developing chronic pain was about 10 percent higher. The authors describe the effect size as modest, and they are candid about the limitations: when CRP was added to a clinical prediction model that already included depression and BMI, it barely improved the model's ability to discriminate between who would and would not develop pain. The marker adds a real signal, but it is not a precise prediction tool on its own.

The study was published open access in The Journal of Pain in October 2026 (Rech et al., 2026, DOI: 10.1016/j.jpain.2026.106376). The authors frame their findings as pointing toward a need for clinically integrated screening that considers biological and psychosocial risk factors together, rather than relying on a single biomarker to identify people at risk of chronic pain. Depression emerged as the strongest single predictor in their analysis, suggesting that the inflammatory and psychosocial pathways to chronic pain are intertwined rather than separate.

Why Inflammation and Pain Are Biologically Connected

The link between systemic inflammation and chronic pain has a well-established mechanistic basis that researchers have been filling in for decades. At the most fundamental level, the immune system and the nervous system share a common chemical language. Cytokines, the signaling proteins that immune cells use to coordinate an inflammatory response, can directly activate and sensitize pain-sensing neurons called nociceptors. When cytokines such as interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha are released locally after tissue injury, they lower the activation threshold of these neurons, making them fire more easily and more intensely. This is why inflamed tissue hurts, and it is part of how pain serves its protective function during healing.

The problem arises when inflammation persists well beyond the point of any acute injury, because the nervous system can undergo lasting changes in response to sustained inflammatory signaling. A landmark 2018 review in Anesthesiology described how neuroinflammation, meaning inflammatory activity within the central nervous system itself, contributes to central sensitization, a state in which the spinal cord and brain become amplified in their processing of pain signals (Ji et al., 2018, PMID 29462012). In a sensitized system, stimuli that would normally be innocuous can be experienced as painful, and pain signals from one area can spread to regions that were never directly injured. The review describes sustained cytokine and chemokine activity in the central nervous system as a driver of widespread chronic pain affecting multiple body sites, which helps explain conditions like fibromyalgia and widespread musculoskeletal pain that do not have a single obvious tissue source.

CRP itself does not directly cause pain, but it is a reliable downstream marker of the inflammatory activity that does. Because CRP is synthesized by the liver in response to signaling from interleukin-6, a cytokine that can directly sensitize pain neurons, CRP levels reflect the same inflammatory environment that is shaping the nervous system's sensitivity to pain. This is part of why CRP has appeared as a predictor in chronic pain studies across different populations and pain conditions, even though CRP is not directly acting on nerve fibers. It is, in effect, a readout of a process that has documented effects on pain biology.

This Is Not the First Study to Find the Link

The new Health and Retirement Study analysis builds on a substantial prior literature linking CRP to chronic pain prevalence and severity across different settings. One of the most carefully powered studies in this area used UK Biobank data from 415,567 participants and examined CRP levels in people reporting nine distinct types of regional chronic pain, including back pain, neck pain, hip pain, knee pain, and others (Farrell et al., 2024, PMID 37741522). After adjusting for a broad range of biopsychosocial factors including depression, anxiety, sleep problems, physical inactivity, smoking, and socioeconomic status, CRP remained significantly higher in most chronic pain groups compared with pain-free controls. The authors described the adjusted association as pointing toward an independent underlying biological mechanism of inflammation in chronic pain, while acknowledging that unmeasured confounders cannot be ruled out.

What distinguishes the new 2026 paper is its longitudinal design. Cross-sectional studies like the UK Biobank analysis can show that inflammation and pain are associated at a given point in time, but they cannot tell you whether elevated inflammation preceded the pain or whether living with chronic pain elevates inflammation. It almost certainly works in both directions, and the relationship is likely bidirectional over time. The Health and Retirement Study design, following people who had no pain at baseline and tracking who developed it, provides stronger evidence that inflammation is present before pain onset rather than purely a consequence of it. That distinction matters for thinking about prevention and early wellness monitoring.

Who Showed the Clearest Risk Patterns

The new study's analysis included a comorbidity-based stratification that revealed some of the most practically useful findings. Rather than treating older adults as a uniform group, the researchers examined how CRP's predictive value varied across people with different combinations of existing health conditions. This approach reflects the reality that older adults rarely come with a clean slate, and that the inflammatory landscape is shaped by conditions like cardiovascular disease, metabolic syndrome, diabetes, and kidney disease, all of which can elevate CRP through mechanisms independent of pain. The title of the paper explicitly references "comorbidity-driven risk profiles," indicating that where you sit on the health spectrum matters a great deal for interpreting what your CRP level predicts.

The study also found that depression was the strongest predictor of incident chronic pain, a finding that is consistent with decades of research on the overlap between pain and mood. This is not merely a statistical inconvenience for the CRP finding; it is a meaningful biological observation. Depression is associated with chronically elevated inflammatory cytokines, and the inflammatory activation that accompanies depression may be part of the same biological thread that links systemic inflammation to pain sensitization. The two pathways converge rather than compete. For someone trying to understand their own risk, this means that addressing inflammation is one meaningful lever among several, and that mental health, sleep quality, physical activity, and body weight are intertwined parts of the same picture.

The Modest Effect Size in Context

It is worth dwelling on what a 10 percent higher incidence rate per CRP unit actually means for an individual person, because the honest answer is: not a great deal in isolation. At the population level, modest effect sizes like this can account for substantial numbers of additional cases across millions of people, which is why researchers care about them. At the individual level, knowing that your CRP is elevated does not predict with any useful precision whether you will or will not develop chronic pain. The authors themselves make this point explicitly by reporting that adding CRP to a clinical model barely moved the discrimination statistics. This is a reason to interpret the finding appropriately, as evidence of a biological link that is real but one among many factors, rather than as grounds for alarm about a single CRP reading.

The appropriate use of this kind of finding is to motivate attention to the underlying inflammatory state as part of an overall wellness picture, not to interpret CRP as a diagnostic test for pain risk. CRP is a general wellness marker reflecting many things simultaneously: adipose tissue mass, dietary patterns, physical activity, sleep quality, smoking, stress, and underlying immune activity. A high CRP reading provides a general signal that something in the body's inflammatory balance is off, and the appropriate response is to think about lifestyle factors that influence inflammation broadly and, when the elevation is persistent, to discuss it with a healthcare provider rather than self-diagnose.

Inflammation Monitoring as Part of a Long-Term Wellness Strategy

Studies like this one make the case for longitudinal tracking of inflammatory markers rather than relying on a single measurement. Because CRP reflects the net output of many lifestyle and health factors at once, following it over time provides information that no single reading can. A person who consistently sees their CRP declining in response to better sleep, reduced stress, regular exercise, or an improved dietary pattern is gathering meaningful evidence that their inflammatory biology is shifting in a healthier direction. A persistent elevation that does not respond to lifestyle changes, by contrast, is a cue to discuss with a clinician what else might be contributing.

The context of chronic pain specifically adds another dimension to this monitoring rationale. Chronic pain is among the most common reasons older adults lose independence, seek medical care, and report diminished quality of life. If a meaningful portion of incident chronic pain in older adults is preceded by measurable systemic inflammation, that window before symptoms develop represents an opportunity to pay attention to inflammatory health. This is not a claim that managing CRP will prevent chronic pain, because the evidence does not support a causal conclusion of that strength. It is an argument that inflammation is a dimension of health worth monitoring, that CRP is the most validated general marker available for doing so, and that the findings from this new study add to the scientific rationale for that kind of proactive attention.

Sources

• Rech L, Garnier J, et al. C-reactive protein and incident chronic pain in older adults: comorbidity-driven risk profiles and implications for preventive screening. The Journal of Pain, 2026;47. DOI: 10.1016/j.jpain.2026.106376. sciencedirect.com/science/article/pii/S152659002600194X
• Farrell SF, Armfield NR, Cabot PJ, et al. C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors. The Journal of Pain. 2024;25(2):476-496. pubmed.ncbi.nlm.nih.gov/37741522
• Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology. 2018;129(2):343-366. pubmed.ncbi.nlm.nih.gov/29462012

Frequently Asked Questions

Does high CRP predict chronic pain?

Elevated CRP is associated with a modestly higher risk of developing chronic pain, according to a new prospective study in The Journal of Pain that followed 1,850 older adults. The incidence rate ratio was 1.10 per unit increase in CRP, which is statistically significant but small in practical terms. CRP alone adds limited predictive value compared with factors like depression and BMI, so it is best understood as one piece of a larger inflammatory and psychosocial picture rather than a precise predictor of pain.

Why does inflammation cause chronic pain?

Inflammatory cytokines can directly lower the activation threshold of pain-sensing neurons, making them fire more readily. When inflammation persists, the nervous system can undergo a process called central sensitization, in which the brain and spinal cord become amplified in their processing of pain signals. This means that sustained systemic inflammation, which CRP reflects, is not just an incidental finding alongside chronic pain but is likely involved in the biological process by which pain becomes persistent.

How can you lower CRP to reduce pain risk?

The lifestyle factors with the strongest evidence for reducing CRP include regular physical activity, achieving or maintaining a healthy weight, improving sleep quality, reducing added sugar and ultra-processed food intake, not smoking, and managing chronic stress. These are the same factors associated with lower chronic pain risk more broadly, which is consistent with the view that inflammation is one shared biological pathway linking lifestyle and long-term health. Any persistent CRP elevation is worth discussing with a healthcare provider to rule out underlying conditions.

Is a single CRP reading enough to assess pain risk?

No. CRP is a highly variable marker that can fluctuate substantially from one measurement to the next based on minor infections, physical activity, menstrual cycle timing, and many other factors. A single high reading may reflect something transient rather than a sustained inflammatory state. Tracking CRP over multiple measurements over time gives a much more meaningful picture of your baseline inflammatory level, which is what the research links to long-term health outcomes including chronic pain risk.